Investor profile
TTP Group
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
TTP Group is an independent technology company based outside Cambridge, UK, founded in 1987, that incubates new technology businesses and invests in early-stage technology companies using its own balance-sheet capital — not external LP funds. The group has created over 20 new businesses spanning healthcare, medtech, life sciences, communications, defence, and industrials, taking innovations from first principles through to market adoption and successful exit. TTP Group's model combines deep technical expertise with commercial insight: portfolio companies are typically conceived and incubated inside TTP's own laboratories, giving them access to TTP's 300-plus scientists and engineers, prototyping facilities, and regulatory expertise alongside equity funding. The strategy concentrates on hard-science, deep-tech enterprises — particularly medical devices, bioprocessing, wireless communications, advanced materials, and environmental sensing — where high IP barriers and complex engineering challenges suit patient, technically literate capital. TTP typically leads or co-leads seed and Series A rounds and reserves follow-on capital for subsequent financing events.
Notable quotes
“This oversubscribed round is a testament to Cellular Origins' exceptional team and innovation. For TTP Group, this demonstrates our unique ability to build and nurture businesses that deliver breakthrough technologies, transform them into market-leading products, and create significant value.”
“LEX Diagnostics is a great example of how TTP turns breakthrough science into valuable new businesses. We have a long history of partnering with industry to incubate technologies from first principles and scaling them into impactful companies. This acquisition demonstrates the strength of that model.”
“At TTP, we identified the opportunity for ultra-fast thermal cycling to unlock the real potential of PCR at the point-of-care. That insight led our scientists and engineers to invent the core technology behind LEX Diagnostics, and TTP spun out the company to bring lab-quality PCR results to clinicians in minutes.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Cellular Origins | Series A | $40m | 2025-12-09 |
| LEX Diagnostics | Incubation / Spin-out | — | 2020-01-01 |
| Cellular Highways | Incubation / Spin-out | — | 2021-01-01 |
| TTP Ventus (Lee Ventus) | Incubation / Spin-out | — | 2019-01-01 |
| TTP Labtech (SPT Labtech) | Incubation / Spin-out | — | 2000-01-01 |
| Displaydata | Series D | $10m | 2013-07-12 |
| CamSemi | Series C | $8m | 2007-10-24 |
| Tonejet | Incubation / Spin-out | — | 2005-01-01 |
| Sphere Fluidics (Sphere Bio) | Series B | $40m | 2021-10-28 |
| Awerian | Incubation / Spin-out | — | 2022-01-01 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Johnson & Johnson Innovation – JJDC | 1 |
| Highland Europe | 1 |
| BGF | 1 |
| NYBC Ventures | 1 |
| Carbon Trust | 1 |
| QinetiQ | 1 |
Fit check
Is TTP Group a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit